Inclacumab is under clinical development by Global Blood Therapeutics and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Inclacumab’s likelihood of approval (LoA) and phase transition for Sickle Cell Disease With Vaso-Occlusive Crisis took place on 26 May 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Inclacumab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Inclacumab overview

Inclacumab is under development for the treatment of vaso-occlusive crisis in patients with sickle cell disease. The drug candidate is a monoclonal antibody and is administered intravenously. RG1512 targets P-selectin.

It was under development for the treatment of acute coronary syndrome, myocardial infarction in patients undergoing percutaneous coronary intervention and prevention of saphenous vein graft disease and peripheral vascular disease/peripheral arterial disease (PAD).

Global Blood Therapeutics overview

Global Blood Therapeutics (GBT) is a clinical-stage biopharmaceutical company. The company offers Voxelotor which is used for the treatment of sickle cell disease, or SCD, in adults and children. GBT’s pipeline also includes GBT021601 which is a next-generation hemoglobin polymerization inhibitor that is in Phase 1 development. The company also develops therapies that are in preclinical and preliminary clinical stages for the treatment of acute and chronic hypoxemic pulmonary disorders. It offers chemical and biological mechanisms for blood-based disorders. GBT is headquartered in South San Francisco, California, the US.

Quick View Inclacumab LOA Data

Report Segments
  • Innovator
Drug Name
  • Inclacumab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Cardiovascular
  • Hematological Disorders
Key Developers
Highest Development Stage
  • Phase III


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.